{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T02:13:26Z","timestamp":1791252806836,"version":"4.1.0"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1765,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2010,11]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      <jats:bold>Radioembolization has been demonstrated to allow locoregional therapy of patients with hepatocellular carcinoma not eligible for transarterial chemoembolization or other local therapies. The aim of this study was to validate evidence of the safety and efficacy of this treatment in a European sample of patients with advanced hepatocellular carcinoma (HCC). Therefore, 108 consecutive patients with advanced HCC and liver cirrhosis were included. Yttrium-90 (Y-90) microspheres were administered in a lobar fashion over the right or left branch of the hepatic artery. The response to treatment was evaluated by computed tomography (CT) imaging applying Response Evaluation Criteria in Solid Tumors (RECIST) and World Health Organization (WHO) criteria with recent European Association for the Study of the Liver \/ National Cancer Institute (EASL\/NCI) amendments. Time to progression (TTP) and overall survival were estimated by the Kaplan-Meier method. In all, 159 treatment sessions were performed ranging between one to three treatments per patient. The mean radiation dose per treatment was 120 (\u00b118) Gy. According to EASL criteria, complete responses were determined in 3% of patients, partial responses in 37%, stable disease 53%, and primary progression in 6% of patients. TTP was 10.0 months, whereas the median overall survival was 16.4 months. No lung or visceral toxicity was observed. The most frequently observed adverse events was a transient fatigue-syndrome.<\/jats:bold>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>\n                      <jats:bold>Radioembolization with Y-90 glass microspheres for patients with advanced HCC is a safe and effective treatment which can be utilized even in patients with compromised liver function. Because TTP and survival appear to be comparable to systemic therapy in selected patients with advanced HCC, randomized controlled trials in combination with systemic therapy are warranted. (Hepatology 2010;52:1741-1749)<\/jats:bold>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/hep.23944","type":"journal-article","created":{"date-parts":[[2010,8,31]],"date-time":"2010-08-31T18:15:16Z","timestamp":1283278516000},"page":"1741-1749","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":376,"title":["Radioembolization with Yttrium-90 Glass Microspheres in Hepatocellular Carcinoma: European Experience on Safety and Long-Term Survival"],"prefix":"10.1097","volume":"52","author":[{"given":"Philip","family":"Hilgard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monia","family":"Hamami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amr El","family":"Fouly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Scherag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Ertle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Till","family":"Heusner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vito R.","family":"Cicinnati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Bockisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Gerken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Antoch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-24-20250312","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1080\/13651820410024058","article-title":"Staging systems in hepatocellular carcinoma.","volume":"7","author":"Pons","year":"2005","journal-title":"HPB (Oxford)"},{"key":"R2-24-20250312","doi-asserted-by":"crossref","first-page":"17341739","DOI":"10.1016\/S0140-6736(02)08649-X","article-title":"Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial.","volume":"359","author":"Llovet","year":"2002","journal-title":"Lancet"},{"key":"R3-24-20250312","first-page":"12561261","article-title":"Groupe dEtude et de Traitement du Carcinome Hepatocellulaire.","volume":"332","year":"1995","journal-title":"N Engl J Med"},{"key":"R4-24-20250312","doi-asserted-by":"crossref","first-page":"614616","DOI":"10.1016\/S0140-6736(09)60381-0","article-title":"Major achievements in hepatocellular carcinoma.","volume":"373","author":"Bruix","year":"2009","journal-title":"Lancet"},{"key":"R5-24-20250312","doi-asserted-by":"crossref","first-page":"378390","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma.","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"R6-24-20250312","doi-asserted-by":"crossref","first-page":"12511278","DOI":"10.1097\/01.RVI.0000235779.88652.53","article-title":"Radioembolization with 90Yttrium microspheres: a stateoftheart brachytherapy treatment for primary and secondary liver malignancies. Part 1: Technical and methodologic considerations.","volume":"17","author":"Salem","year":"2006","journal-title":"J Vasc Interv Radiol"},{"key":"R7-24-20250312","doi-asserted-by":"crossref","first-page":"7181","DOI":"10.1002\/hep.21980","article-title":"Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis.","volume":"47","author":"Kulik","year":"2008","journal-title":"Hepatology"},{"key":"R8-24-20250312","first-page":"3754","article-title":"Selective internal radiotherapy (radioembolization) and radiation therapy for HCCcurrent status and perspectives.","volume":"47","author":"Hilgard","year":"2009","journal-title":"Z Gastroenterol"},{"key":"R9-24-20250312","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.ijrobp.2006.11.060","article-title":"Recommendations for radioembolization of hepatic malignancies using yttrium90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium.","volume":"68","author":"Kennedy","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R10-24-20250312","doi-asserted-by":"crossref","first-page":"207214","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","article-title":"Reporting results of cancer treatment.","volume":"47","author":"Miller","year":"1981","journal-title":"Cancer"},{"key":"R11-24-20250312","doi-asserted-by":"crossref","first-page":"228247","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"R12-24-20250312","first-page":"421430","article-title":"Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona2000 EASL conference. European Association for the Study of the Liver.","volume":"35","author":"Bruix","year":"2001","journal-title":"J Hepatol"},{"key":"R13-24-20250312","first-page":"698711","article-title":"Design and endpoints of clinical trials in hepatocellular carcinoma.","volume":"100","author":"Llovet","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"R14-24-20250312","doi-asserted-by":"crossref","first-page":"16271639","DOI":"10.1097\/01.RVI.0000184594.01661.81","article-title":"Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival.","volume":"16","author":"Salem","year":"2005","journal-title":"J Vasc Interv Radiol"},{"key":"R15-24-20250312","doi-asserted-by":"crossref","first-page":"224230","DOI":"10.1016\/j.jvir.2009.10.013","article-title":"Comparison of yttrium90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma.","volume":"21","author":"Kooby","year":"2010","journal-title":"J Vasc Interv Radiol"},{"key":"R16-24-20250312","doi-asserted-by":"crossref","first-page":"19201928","DOI":"10.1111\/j.1600-6143.2009.02695.x","article-title":"A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization.","volume":"9","author":"Lewandowski","year":"2009","journal-title":"Am J Transplant"},{"key":"R17-24-20250312","doi-asserted-by":"crossref","first-page":"5264","DOI":"10.1053\/j.gastro.2009.09.006","article-title":"Radioembolization for hepatocellular carcinoma using Yttrium90 microspheres: a comprehensive report of longterm outcomes.","volume":"138","author":"Salem","year":"2010","journal-title":"Gastroenterology"},{"key":"R18-24-20250312","doi-asserted-by":"crossref","first-page":"431438","DOI":"10.1097\/COC.0b013e318168ef65","article-title":"Incidence of radiation pneumonitis after hepatic intraarterial radiotherapy with yttrium90 microspheres assuming uniform lung distribution.","volume":"31","author":"Salem","year":"2008","journal-title":"Am J Clin Oncol"},{"key":"R19-24-20250312","doi-asserted-by":"crossref","first-page":"12161220","DOI":"10.1111\/j.1572-0241.2007.01172.x","article-title":"Gastroduodenal injury after radioembolization of hepatic tumors.","volume":"102","author":"Carretero","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"R20-24-20250312","doi-asserted-by":"crossref","first-page":"688692","DOI":"10.2967\/jnumed.108.058347","article-title":"SPECTCT with 99mTcMAA in radioembolization with 90Y microspheres in patients with hepatocellular cancer.","volume":"50","author":"Hamami","year":"2009","journal-title":"J Nucl Med"},{"key":"R21-24-20250312","doi-asserted-by":"crossref","first-page":"14941500","DOI":"10.1016\/j.ijrobp.2008.10.005","article-title":"Treatment parameters and outcome in 680 treatments of internal radiation with resin 90Ymicrospheres for unresectable hepatic tumors.","volume":"74","author":"Kennedy","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.23944","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-201011000-00024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T07:04:08Z","timestamp":1741763048000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-201011000-00024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.23944","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2010,11]]}}}